Stage I Clear Cell and Serous Uterine Carcinoma: What Is the Right Adjuvant Therapy?

Round 1

Reviewer 1 Report

Minor comments:

1. On Table 1, do authors have patients' data such as BMI, smoking and alcohol history?

2. Any estrogen receptor and progesterone receptor staining available?

3. Why chose age 70 as cutoff and comparison?

4. Any race group among patients?

5. Any neuropathology report among patients?

Author Response

Dear reviewer,

Thank you for taking the time to review my work and for your questions.

Please find my response in the attached file. Do not hesitate if you have further questions.

Kind regards.

Author Response File: Author Response.docx

Reviewer 2 Report

The manuscript "Stage I clear cell and serous uterine carcinoma: What is the right adjuvant therapy?" is an interesting manuscript on the evaluation of the survival outcomes of patients with FIGO stage I clear-cell and serous uterine carcinoma according to the type of adjuvant treatment received. The work is well performed and structured. The design of the project is appropriate and the results are significant. The language is acceptable and the quality of the tables and flow charts is satisfactory. The statistical analysis is well conducted. The only limitation of this work is related to its retrospective nature and to the fact that is a single-center study, but it is otherwise interesting the number of patients for this specific pathology is high in comparison with previous studies. It is a valid work and it could be accepted for publication in your esteemed journal.

Author Response

Thank you for taking the time to review our article and for your comments on our work.

Cordially yours.

Reviewer 3 Report

Dear authors

 

congratulation to this hudge work and its very usefull conclusion for our day to day clinical practice.

My only comment would be on the lack of molecular information of these different patients, and in particular to confirm the presence or not of a p53 mutation which has been shown to be a good indication for adding chemotherapy to radiotherapy. We can assume that serous carcinomas are carriers, but what about clear cells?

Author Response

First of all, thank you for taking time to review our article.

Concerning the lack of molecular information, the data were collected between 2003 and 2020. In our center, anatomopathologists have begun to look for the molecular profile since 2021 after the new ESGO guidelines, that's why the information doesn't appear in this article.

It is known that p53 mutation is highly carried in serous carcinomas and helps anatomopathologists to identify mainly serous histologies.

Clear cells are less carriers of this mutation than serous carcinomas. We can assume it is one of the reasons why they have lower chemosensitivity.

Cordially yours.